I Stephenson

Summary

Affiliation: University Hospital Aintree
Country: UK

Publications

  1. ncbi Clinical evaluation of vaccines for pandemic influenza H5N1
    Manish Pareek
    Infectious Diseases Unit, University Hospitals Leicester, Leicester LE1 5WW
    Br J Hosp Med (Lond) 68:80-4. 2007
  2. ncbi Confronting the avian influenza threat: vaccine development for a potential pandemic
    Iain Stephenson
    Influenza Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Lancet Infect Dis 4:499-509. 2004
  3. pmc Jaundice in primary school pupils
    I Stephenson
    Department of Infectious Diseases and Tropical Medicine, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Postgrad Med J 78:56, 59. 2002
  4. ncbi The epidemiology of influenza
    I Stephenson
    Specialist Registrar in Infectious Diseases, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Occup Med (Lond) 52:241-7. 2002
  5. ncbi Healthcare workers and their attitudes to influenza vaccination
    I Stephenson
    Department of Infectious Diseases and Tropical Medicine, Leicester Royal Infirmary, Leicester LE1 5WW
    Commun Dis Public Health 5:247-52. 2002
  6. ncbi Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza
    K G Nicholson
    Infectious Diseases Unit, Leicester Royal Infirmary, LE1 5WW, Leicester, UK
    Lancet 357:1937-43. 2001
  7. ncbi Influenza: vaccination and treatment
    I Stephenson
    Dept of Infection and Tropical Medicine, Leicester Royal Infirmary, UK
    Eur Respir J 17:1282-93. 2001
  8. ncbi Influenza: current threat from avian influenza
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Br Med Bull 75:63-80. 2005
  9. ncbi Are we ready for pandemic influenza H5N1?
    Iain Stephenson
    Leicester Royal Infirmary, Level 6, Windsor Building, Leicester, LE1 5WW, UK
    Expert Rev Vaccines 4:151-5. 2005
  10. ncbi Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Lancet 362:1959-66. 2003

Collaborators

Detail Information

Publications25

  1. ncbi Clinical evaluation of vaccines for pandemic influenza H5N1
    Manish Pareek
    Infectious Diseases Unit, University Hospitals Leicester, Leicester LE1 5WW
    Br J Hosp Med (Lond) 68:80-4. 2007
    ..In 2004 the virus re-emerged among poultry and migratory birds in Asia and has spread into Europe and Africa, raising concerns that an H5 pandemic is imminent...
  2. ncbi Confronting the avian influenza threat: vaccine development for a potential pandemic
    Iain Stephenson
    Influenza Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Lancet Infect Dis 4:499-509. 2004
    ..Adjuvanted or whole-virus preparations may improve immunogenicity and allow sparing of antigen...
  3. pmc Jaundice in primary school pupils
    I Stephenson
    Department of Infectious Diseases and Tropical Medicine, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Postgrad Med J 78:56, 59. 2002
  4. ncbi The epidemiology of influenza
    I Stephenson
    Specialist Registrar in Infectious Diseases, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Occup Med (Lond) 52:241-7. 2002
    ..The occurrence in Hong Kong in 1997 of avian influenza H5N1 in man, which resulted in six deaths, served to remind us of the importance of continuing surveillance and preparation for the next pandemic...
  5. ncbi Healthcare workers and their attitudes to influenza vaccination
    I Stephenson
    Department of Infectious Diseases and Tropical Medicine, Leicester Royal Infirmary, Leicester LE1 5WW
    Commun Dis Public Health 5:247-52. 2002
    ..Simply raising awareness may not translate into increased uptake. Absenteeism was attributed to vaccine-related adverse effects by 11/83 (13%) vaccinees, resulting in 0.46 workdays lost per dose administered...
  6. ncbi Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza
    K G Nicholson
    Infectious Diseases Unit, Leicester Royal Infirmary, LE1 5WW, Leicester, UK
    Lancet 357:1937-43. 2001
    ..We did an observer-blind, phase I, randomised trial in healthy volunteers to assess safety, tolerability, and antigenicity of MF59-adjuvanted and non-adjuvanted vaccines...
  7. ncbi Influenza: vaccination and treatment
    I Stephenson
    Dept of Infection and Tropical Medicine, Leicester Royal Infirmary, UK
    Eur Respir J 17:1282-93. 2001
    ....
  8. ncbi Influenza: current threat from avian influenza
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Br Med Bull 75:63-80. 2005
    ..Oseltamivir has been stockpiled as part of influenza pandemic preparedness planning; however, the emergence of drug resistance may limit its clinical use...
  9. ncbi Are we ready for pandemic influenza H5N1?
    Iain Stephenson
    Leicester Royal Infirmary, Level 6, Windsor Building, Leicester, LE1 5WW, UK
    Expert Rev Vaccines 4:151-5. 2005
    ..Pandemic preparedness plans have been developed by national and international authorities but may be compromised by a lack of readily available interventions...
  10. ncbi Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Lancet 362:1959-66. 2003
    ..In 1999, avian influenza A/Hong Kong/1073/99 (H9N2) virus emerged as a pandemic threat to human beings. We aimed to assess safety, tolerability, and antigenicity of whole virus and subunit H9N2 vaccines in healthy volunteers...
  11. ncbi Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy
    Iain Stephenson
    Influenza Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    J Infect Dis 191:1210-5. 2005
    ..0004), and 43% (P = .0128) in 14 subjects, respectively, compared with 27%, 27%, 0%, and 0% in 11 who received nonadjuvanted vaccine. These findings have implications for the rational design of pandemic vaccines against influenza H5...
  12. ncbi Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, LE1 5WW, Leicester, UK
    Vaccine 21:1687-93. 2003
    ..001). MF59 significantly increased GMTs of antibody when compared to non-adjuvanted vaccine (P<0.001)...
  13. ncbi H5N1 vaccines: how prepared are we for a pandemic?
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Lancet 368:965-6. 2006
  14. doi Willingness of healthcare workers to accept voluntary stockpiled H5N1 vaccine in advance of pandemic activity
    Manish Pareek
    Infectious Diseases Unit, University Hospitals Leicester, Leicester LE1 5WW, UK
    Vaccine 27:1242-7. 2009
    ..A majority of healthcare workers are amenable to accept stockpiled H5N1 vaccine if offered in advance of pandemic activity...
  15. ncbi Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study
    Iain Stephenson
    Infectious Diseases Unit, University Hospitals Leicester, Leicester LE1 5WW, UK
    Vaccine 25:4056-63. 2007
    ..This study raises concern about comparability of serology results from H5N1 vaccine trials and it is proposed that an International Standard for influenza H5N1 antibody is developed...
  16. ncbi Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses
    Xiuhua Lu
    Influenza Branch, Centers for Disease Control and Prevention, USA
    Vaccine 24:6588-93. 2006
    ..These results demonstrated that vaccination of mice with H5 IIV or LAIV induced a high degree of cross-protection from illness and death following lethal challenges with a heterologous H5N1 virus...
  17. ncbi Use of neuraminidase inhibitors to combat pandemic influenza
    Jane Democratis
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    J Antimicrob Chemother 58:911-5. 2006
    ....
  18. pmc Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW, United Kingdom
    J Virol 80:4962-70. 2006
    ..The addition of the biovector to the vaccine given with 30 microg LTK63 enhanced mucosal IgA responses to A/Duck/Singapore (H5N3) (P=0.0491) and B/Guandong (P=0.0028) but not to A/Panama (H3N2). All vaccines were well tolerated...
  19. pmc Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice
    Mary A Hoelscher
    Influenza Branch, Division of Rickettsial and Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Lancet 367:475-81. 2006
    ..However, currently licensed human vaccines are subtype-specific and do not protect against these H5N1 viruses. We aimed to develop an influenza vaccine and assessed its immunogenicity and efficacy to confer protection in BALB/c mice...
  20. doi Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children
    Iain Stephenson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester, UK
    Clin Infect Dis 48:389-96. 2009
    ..We investigated the emergence of drug-resistant infection in children treated with a tiered weight-based dosing regimen...
  21. ncbi Development of vaccines against influenza H5
    Iain Stephenson
    Lancet Infect Dis 6:458-60. 2006
  22. ncbi Development and evaluation of influenza pandemic vaccines
    Iain Stephenson
    Lancet Infect Dis 6:71-2. 2006
  23. ncbi Transmission of equine influenza virus to dogs
    P C Crawford
    College of Veterinary Medicine, University of Florida, Gainesville, FL 32611, USA
    Science 310:482-5. 2005
    ..Evidence of infection in pet dogs suggests that this infection may also become enzootic in this population...
  24. doi Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1
    Iain Stephenson
    N Engl J Med 359:1631-3. 2008
  25. pmc Human metapneumovirus as a cause of community-acquired respiratory illness
    Joanne Stockton
    Public Health Laboratory Service Central Public Health Laboratory, London, United Kingdom
    Emerg Infect Dis 8:897-901. 2002
    ..2%) patients. HMPV appears to be associated with community-acquired ARTI. The extent of illness and possible complications related to this new human virus need to be clarified...